[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transthyretin-amyloidosis-attr-with-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transthyretin-amyloidosis-attr-with-cardiomyopathy":57},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100525968",false,"NCT06128629","MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)","MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)","Inclusion Criteria:\n\n* Documented diagnosis of ATTR amyloidosis with cardiomyopathy\n* Medical history of heart failure (HF)\n* Symptoms of HF are optimally managed and clinically stable within 28 days prior to administration of study intervention\n* Screening NT-proBNP, a blood marker of HF severity, greater than or equal to 600 pg\u002FmL and less than 10,000 pg\u002FmL\n\nExclusion Criteria:\n\n* New York Heart Association (NYHA) Class IV HF\n* Polyneuropathy Disability score of IV (confined to wheelchair or bed)\n* Has hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection\n* History of active malignancy within 3 years prior to screening\n* RNA silencer therapy (patisiran, inotersen and\u002For eplontersen) within 12 months prior to dosing. Any prior vutrisiran use is not allowed\n* Initiation of tafamidis or acoramidis within 56 days prior to study dosing\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m\\^2\n* History of liver disease\n* Uncontrolled blood pressure\n* Unable or unwilling to take vitamin A supplementation for the duration of the study","ALL","18 Years","90 Years",{"count":19,"type":20},1200,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.",[26],"Transthyretin Amyloidosis (ATTR) With Cardiomyopathy",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"TTR","Amyloidosis","Cardiomyopathy","NTLA-2001","ATTR-CM","Transthyretin","ATTR","TTR-mediated amyloidosis","Amyloidosis, Hereditary","Amyloidosis, Hereditary, Transthyretin-Related Amyloidosis","Transthyretin amyloid cardiomyopathy","TTR cardiomyopathy","Wild-type TTR","V122I","Amyloidosis, Wild Type","CRISPR\u002FCas9","RECRUITING","2026-03-23",{"date":47,"type":48},"2026-03-27","ACTUAL",{"date":50,"type":48},"2023-12-13",{"date":52,"type":20},"2028-04",{"name":54,"class":55},"Intellia Therapeutics","INDUSTRY",132,""]